BioCryst Pharma rises after lifting annual sales forecast for skin disease drug

Shares of drugmaker BioCryst Pharmaceuticals BCRX.O rise 17.5% to $10.49 premarket

BCRX raises its 2025 revenue forecast for its skin disease drug, Orladeyo, to between $580 million and $600 million, compared with previous projection of $535 million to $550 million

Analysts on average estimate Orladeyo's 2025 revenue to be $514.29 million

Co posts Q1 total revenue of $145.5 million, compared with $92.8 million a year ago

BCRX reports Q1 revenue for Orladeyo of $134.2 million, compared with $88.9 million a year ago

"Orladeyo's revenue growth was driven by moving patients from free drug to paid at a much faster rate than we expected, resulting in a substantial increase to our annual guidance as we also move closer to peak sales of $1 billion," says CEO Jon Stonehouse

As of last close, BCRX rose 18.8% YTD